STOCK TITAN

Clarivate Plc - CLVT STOCK NEWS

Welcome to our dedicated page for Clarivate Plc news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate Plc stock.

About Clarivate Plc

Clarivate Plc (NYSE: CLVT) is a leading global provider of transformative intelligence, delivering enriched data, insights, analytics, and workflow solutions to accelerate innovation across academia, intellectual property (IP), life sciences, and government sectors. With a mission to empower organizations and researchers to bring life-changing ideas to market faster, Clarivate offers a comprehensive suite of trusted brands, including Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor®, and Techstreet™. These solutions enable customers to streamline research, manage intellectual property, and optimize pharmaceutical development.

Core Business Areas

Clarivate operates across three primary segments:

  • Academia & Government: Supporting academic institutions and government bodies with data-driven insights, library services, and discovery platforms to enhance research and learning outcomes.
  • Intellectual Property: Providing tools for patent analytics, trademark research, and IP lifecycle management, empowering organizations to protect and monetize their innovations.
  • Life Sciences & Healthcare: Delivering real-world data, analytics, and workflow solutions to pharmaceutical and biotech companies, aiding in drug discovery, regulatory compliance, and market access.

Revenue Model and Market Position

Clarivate primarily generates revenue through subscription-based services, ensuring a predictable and recurring income stream. Its portfolio also includes licensing, transactional sales, and consulting services. With operations in over 100 countries and a customer base spanning academia, government, law, healthcare, and life sciences, Clarivate is uniquely positioned as a critical enabler of innovation. The company’s focus on integrating artificial intelligence (AI) and real-world data into its offerings distinguishes it from competitors in the knowledge economy.

Strategic Initiatives

Clarivate is actively pursuing a Value Creation Plan to enhance its financial performance and operational efficiency. Key initiatives include:

  • Subscription Revenue Growth: Transitioning from low-margin transactional products to high-margin subscription-based solutions.
  • Portfolio Rationalization: Streamlining its product offerings to focus on high-growth, high-impact areas.
  • AI-Driven Innovation: Leveraging advanced technologies like AI-powered patent search and real-world data analytics to enhance customer decision-making.
  • Sales Execution: Realigning account management models and investing in customer success teams to improve client engagement and retention.

Challenges and Opportunities

While Clarivate faces challenges such as fluctuating transactional revenues and market competition, its strategic focus on innovation and recurring revenue streams positions it for long-term growth. The company’s ability to integrate AI and real-world data into its solutions offers significant opportunities to address emerging customer needs and expand its market share.

Competitive Landscape

Clarivate competes with other data and analytics providers like Elsevier, Thomson Reuters, and Springer Nature. Its differentiation lies in its comprehensive suite of products, trusted brands, and commitment to innovation. By focusing on customer-centric solutions and leveraging advanced technologies, Clarivate continues to strengthen its competitive position.

Conclusion

Clarivate Plc is more than a data provider; it is a catalyst for innovation, enabling organizations to accelerate the journey from idea to impact. With a robust portfolio of solutions, a strategic focus on subscription revenue, and a commitment to leveraging cutting-edge technologies, Clarivate remains a pivotal player in the global knowledge economy.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
none
-
Rhea-AI Summary

Clarivate Plc (NYSE: CLVT) has announced the pricing of an underwritten public offering of 25,000,000 ordinary shares by affiliated funds of Onex Corporation and Baring Private Equity Asia. The offering is set to close on September 14, 2021, pending customary conditions. An additional 3,750,000 shares may be purchased at the underwriters' discretion. Clarivate will not sell any shares, with proceeds solely benefiting the Selling Shareholders. Citigroup and Barclays are acting as joint book-running managers for this offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.97%
Tags
none
-
Rhea-AI Summary

On September 9, 2021, Clarivate Plc (NYSE: CLVT) announced an underwritten public offering of 25 million ordinary shares, managed by Citigroup and Barclays. The offering includes a 30-day option for underwriters to purchase an additional 3.75 million shares. The proceeds from this offering will be received entirely by the Selling Shareholders, Onex Corporation and Baring Private Equity Asia Group Ltd. The sale will occur under an effective shelf registration statement, and investors are encouraged to review all related documents filed with the SEC for complete information.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.97%
Tags
none
Rhea-AI Summary

Clarivate Plc (NYSE: CLVT) announced that Jerre Stead, Executive Chairman and CEO, along with CFO Richard Hanks, will speak at the Barclays Global Financial Services Conference on September 15, 2021, at 11:15 AM ET. A live webcast will be available on their Investor Relations page, with a replay accessible for 30 days post-event. Clarivate is dedicated to accelerating innovation by providing trusted information and insights to help customers navigate complex problems in science and intellectual property.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
conferences
-
Rhea-AI Summary

On August 19, 2021, Clarivate Plc (NYSE: CLVT) announced the successful settlement of private exchange offers for its outstanding 3.875% Senior Secured Notes due 2028 and 4.875% Senior Notes due 2029. Approximately 92.1% of these notes were tendered, allowing the issuance of new notes totaling around $921 million each. The new notes extend the redemption deadline to April 29, 2022. Additionally, a notice of redemption for untendered notes was sent out, with a redemption date set for August 23, 2021. These offers were conducted without registration under the U.S. Securities Act, targeting eligible holders only.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.22%
Tags
none
-
Rhea-AI Summary

Clarivate announced the expiration of two private exchange offers for outstanding notes as of August 13, 2021. The offers, which affected the 3.875% Senior Secured Notes due 2028 and 4.875% Senior Notes due 2029, allowed for the exchange of old notes for new notes with an extended redemption date to April 29, 2022. A principal amount of $920,897,000 for the 3.875% notes and $920,349,000 for the 4.875% notes is expected to be accepted. The settlement date is anticipated on August 19, 2021, with no cash proceeds to Clarivate from the exchange.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.45%
Tags
none
Rhea-AI Summary

Clarivate Plc (NYSE: CLVT) has announced an exchange offer for two series of its outstanding notes, totaling $2 billion, as part of its ongoing acquisition of ProQuest. The exchange is in response to a second request for documents from the FTC, extending the acquisition completion date to December 31, 2021. If the acquisition is not finalized by this date, the company may redeem the old notes. The new notes will mirror the old ones, with terms extending up to April 29, 2022, and will mature shortly after the old notes. The exchange offers are set to expire on August 13, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.04%
Tags
none
-
Rhea-AI Summary

Clarivate Plc (NYSE:CLVT) has acquired Bioinfogate, a provider of analytics solutions in life sciences, including the OFF-X™ portal. The OFF-X portal is a significant resource, containing over 1.2 million safety alerts related to 23,000 drugs and biologics. This acquisition aims to enhance drug toxicity data integration across the life science cycle, allowing for improved decision-making in drug development. Although financial terms were not disclosed, the acquisition is expected to strengthen Clarivate's offerings, particularly in translational safety intelligence.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.11%
Tags
-
Rhea-AI Summary

Clarivate Plc (NYSE: CLVT; CLVT PR A) announced a $250 million share repurchase program to be executed through October 31, 2021. The Board of Directors expressed confidence in the company's growth prospects and stated that this buyback represents an attractive investment opportunity. The purchases will be funded with existing cash balances, reflecting strong earnings and cash flow, as noted by Executive Chairman and CEO Jerre Stead.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
buyback
Rhea-AI Summary

Clarivate reported strong Q2 2021 results, with revenues of $445.6 million, a 62.9% increase year-over-year. Adjusted EBITDA reached $189.0 million (up 88.8%). Despite a net loss of $82.2 million, adjusted net income was $110.0 million, a 58.3% rise. The company saw organic revenue growth of 5% at constant currency. Cash flow from operations increased to $261.7 million. Looking ahead, Clarivate expects organic revenue growth for 2021 to be at the upper end of 6% to 8%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.83%
Tags
none

FAQ

What is the current stock price of Clarivate Plc (CLVT)?

The current stock price of Clarivate Plc (CLVT) is $4.21 as of March 3, 2025.

What is the market cap of Clarivate Plc (CLVT)?

The market cap of Clarivate Plc (CLVT) is approximately 3.0B.

What does Clarivate Plc do?

Clarivate provides data, insights, and workflow solutions to accelerate innovation in academia, intellectual property, and life sciences.

How does Clarivate generate revenue?

Clarivate primarily generates revenue through subscription-based services, licensing, and consulting, ensuring a recurring income stream.

What industries does Clarivate serve?

Clarivate serves academia, government, intellectual property, life sciences, and healthcare sectors, offering tailored solutions for each industry.

What are Clarivate’s key brands?

Clarivate’s key brands include Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor®, and Techstreet™.

What is Clarivate’s Value Creation Plan?

The Value Creation Plan focuses on subscription revenue growth, portfolio rationalization, AI-driven innovation, and improved sales execution.

How does Clarivate use AI in its products?

Clarivate integrates AI into solutions like patent search and real-world data analytics to enhance decision-making and innovation workflows.

What challenges does Clarivate face?

Clarivate faces challenges such as fluctuating transactional revenues, market competition, and the need for continuous product innovation.

Who are Clarivate’s competitors?

Clarivate competes with companies like Elsevier, Thomson Reuters, and Springer Nature in the data and analytics space.

What makes Clarivate unique?

Clarivate’s comprehensive product portfolio, trusted brands, and focus on AI-driven innovation set it apart from competitors.

What are Clarivate’s future growth areas?

Clarivate aims to grow through subscription-based solutions, AI-powered innovation, and expanding its presence in high-impact sectors like life sciences.
Clarivate Plc

NYSE:CLVT

CLVT Rankings

CLVT Stock Data

3.00B
366.77M
16.38%
92.68%
6.23%
Information Technology Services
Services-computer Processing & Data Preparation
Link
United Kingdom
ST. HELIER